Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pentostatin for High Risk or Refractory Chronic GVHD in Children
NCT00144430Phase 2Completed
- Sponsor
- Ann & Robert H Lurie Children's Hospital of Chicago
- Start
- Jan 2004
- Primary completion
- Aug 2008
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pentostatin in chronic graft-versus-host disease (cGVHD), sponsored by Ann & Robert H Lurie Children's Hospital of Chicago. Primary endpoint: Response Rate (CR and PR) at 52 weeks. Started Jan 2004; status: completed.
02
Drugs
pentostatin
03
Conditions
chronic graft-versus-host disease (cGVHD)
Beyond the preview
Go deeper on NCT00144430.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00144430.